**Question:** True about tumor lysis syndrome -

A. It is a condition caused by rapid tumor cell death.
B. It typically occurs in patients with acute leukemia.
C. Tumor lysis syndrome (TLS) is a rare complication of cancer treatment.
D. The main treatment focus is on managing kidney dysfunction.

**Correct Answer:** B. It typically occurs in patients with acute leukemia.

**Core Concept:**
Tumor Lysis Syndrome (TLS) is a potentially life-threatening complication that can occur in patients with rapidly dividing tumors, particularly in those with acute leukemia. When tumor cells die rapidly, they release a large amount of their contents into the bloodstream, leading to a cascade of electrolyte imbalances, acidosis, and kidney dysfunction.

**Why the Correct Answer is Right:**
Acute leukemia is a type of cancer where there is rapid proliferation of immature blood cells in the bone marrow and blood. When patients with acute leukemia undergo therapy, the rapid cell death leads to the release of a large amount of cellular components into the bloodstream, resulting in TLS. In contrast, TLS is less likely to occur in patients with other types of cancer or in those receiving slower-acting treatments.

**Why Each Wrong Option is Incorrect:**

A. While TLS can occur in patients with rapidly dividing tumors, stating that it is only a condition caused by rapid tumor cell death is too narrow. The condition can affect various types of cancer patients, not just those with acute leukemia.
C. Although TLS can be a complication of cancer treatment, it is not exclusively rare and only occurs in patients undergoing cancer treatment.
D. Managing kidney dysfunction is an essential part of TLS management, but stating that the main treatment focus is solely on kidney dysfunction is inaccurate. Treatment aims to prevent and manage electrolyte imbalances, acidosis, and kidney dysfunction to prevent complications.

**Clinical Pearl:**
Tumor lysis syndrome is a critical complication that healthcare professionals must recognize and manage promptly. Rapidly dividing tumors, particularly in patients with acute leukemia, are at a higher risk for TLS. Effective treatment involves managing electrolyte imbalances, acidosis, and kidney dysfunction to prevent complications and ensure patient safety.